QuidelOrtho Corporation (QDEL)
NASDAQ: QDEL · Real-Time Price · USD
24.40
+0.96 (4.10%)
Aug 7, 2025, 4:00 PM - Market closed
Satixfy Communications Revenue
QuidelOrtho had revenue of $613.90M in the quarter ending June 29, 2025, a decrease of -3.63%. This brings the company's revenue in the last twelve months to $2.74B, down -3.28% year-over-year. In the year 2024, QuidelOrtho had annual revenue of $2.78B, down -7.17%.
Revenue (ttm)
$2.74B
Revenue Growth
-3.28%
P/S Ratio
0.60
Revenue / Employee
$415,394
Employees
6,600
Market Cap
1.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 29, 2024 | 2.78B | -214.90M | -7.17% |
Dec 31, 2023 | 3.00B | -268.20M | -8.21% |
Jan 1, 2023 | 3.27B | 1.57B | 92.28% |
Jan 2, 2022 | 1.70B | 36.90M | 2.22% |
Jan 3, 2021 | 1.66B | 1.13B | 210.66% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
QDEL News
- 2 days ago - QuidelOrtho Corporation (QDEL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - QuidelOrtho Reports Second Quarter 2025 Financial Results - PRNewsWire
- 9 days ago - QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™ - PRNewsWire
- 14 days ago - Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast - PRNewsWire
- 16 days ago - QuidelOrtho to Report Second Quarter 2025 Financial Results - PRNewsWire
- 21 days ago - Real Labs, Actual Decisions With Actionable Six Sigma Metrics - PRNewsWire
- 24 days ago - QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA) - PRNewsWire
- 4 weeks ago - QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs - PRNewsWire